Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies.

@article{Reinisch2012LongtermIM,
  title={Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies.},
  author={Walter Reinisch and W J Sandborn and P. R. Rutgeerts and Brian G Feagan and Daniel Rachmilewitz and S B Hanauer and Gary R. Lichtenstein and Willem J. S. de Villiers and Marion A. Blank and Yinghua Lang and Jewel Johanns and Jean Fr{\'e}d{\'e}ric Colombel and Daniel H. Present and Bruce E Sands},
  journal={Inflammatory bowel diseases},
  year={2012},
  volume={18 2},
  pages={
          201-11
        }
}
BACKGROUND The aim was to evaluate long-term efficacy, quality of life, and safety in ulcerative colitis patients who received infliximab during the ACT-1 and -2 extension studies. METHODS Adults with moderate-to-severely active ulcerative colitis in the 54-week ACT-1 and 30-week ACT-2 studies who achieved benefit from infliximab were eligible to participate in extension studies and receive up to 3 additional years of therapy. Patients received randomized study medication until all sites were… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 63 extracted citations

Second Korean guidelines for the management of ulcerative colitis

Intestinal research • 2017
View 4 Excerpts
Highly Influenced

Surgical management of ulcerative colitis in the era of biologicals.

Inflammatory bowel diseases • 2015
View 3 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…